Tarsier Pharma Ltd.

F-1/A amended

Price $9.00 · Range $8.00 to $10.00 · 5,555,555 shares · Gross proceeds $49,999,995

F-1/A amended

Price $9.00 · Range $8.00 to $10.00 · 5,555,555 shares · Gross proceeds $49,999,995

Tarsier Pharma Ltd. is seeking regulatory approval for its product candidate TRS01, following a Phase 3 trial that failed to meet its primary endpoint. The FDA granted a Special Protocol Assessment (SPA) for a revised trial design focused on safety, but uncertainties remain regarding future trial outcomes and regulatory approval. The company also faces risks related to clinical development, commercialization, and reliance on post-hoc data analyses. TRS02, a second product candidate, is in development for ocular diseases, but its efficacy and safety profiles are unproven. The company emphasizes the need for successful clinical trials, regulatory compliance, and market acceptance to avoid material harm to its business.

F-1/A amended

Tarsier Pharma Ltd. filed Amendment No. 3 to its F-1 registration statement on June 16, 2026, primarily to include Exhibit 10.10 and amend the exhibit index. The prospectus itself remains unchanged from the June 8, 2026 filing, with revisions limited to the cover page, explanatory note, and Part II. The amendment focuses on updating legal and regulatory disclosures related to indemnification, exculpation, and recent unregistered securities offerings.

F-1/A amended

Price $9.00 · Range $8.00 to $10.00 · 5,000,000 shares · Gross proceeds $45,000,000

Tarsier Pharma Ltd. is seeking regulatory approval for its lead product candidate, TRS01, a treatment for non-infectious uveitis, following a Phase 3 trial that failed to meet its primary endpoint. The company has secured a Special Protocol Assessment (SPA) agreement from the FDA for a revised Phase 3 trial focusing on safety as the primary endpoint, though uncertainty remains about regulatory approval. Risks include clinical trial failures, reliance on post-hoc data, challenges in commercialization, and potential adverse events. The company also faces hurdles in manufacturing, marketing, and securing reimbursement for its products. TRS02, a second product candidate, is in earlier development stages with similar risks.

FWP supplemental

Price $9.00 · Range $8.00 to $10.00 · 5,000,000 shares · Gross proceeds $45,000,000

Tarsier Pharma Ltd. is conducting an IPO offering 5,000,000 ordinary shares with a $8.00-$10.00 price range, aiming to raise $45M. Proceeds will fund TRS01's Phase 3 development, NDA preparation, TRS02 R&D, debt repayment, and working capital. The lead underwriter is Konik Capital Partners. The filing highlights TRS01's Phase 3 trial results, IOP safety profile, and potential as a first-line treatment for uveitic glaucoma.

F-1/A amended

Price $9.00 · Range $8.00 to $10.00 · 5,000,000 shares · Gross proceeds $45,000,000

Tarsier Pharma Ltd. seeks FDA approval for TRS01, a novel therapeutic for ocular inflammation, while highlighting risks related to clinical trial outcomes, regulatory hurdles, and reliance on a single new chemical entity (NCE). The filing emphasizes challenges in achieving regulatory approval, potential delays in commercialization, and the impact of adverse events or manufacturing changes. The company also addresses uncertainties around preliminary data, post-market requirements, and the necessity of securing product naming approvals.

F-1 filed

Tarsier Pharma Ltd. is conducting an initial public offering (IPO) of its ordinary shares, aiming to list on the NYSE American under the symbol 'TARX'. The company is developing TRS01, a novel therapy for non-infectious anterior uveitis, including uveitic glaucoma, with a Phase 3 trial designed per FDA's Special Protocol Assessment (SPA) agreement. The offering is contingent on NYSE listing, and the company faces risks related to clinical trial outcomes, regulatory approvals, and its status as a foreign private issuer with reduced U.S. reporting requirements.

DRS/A amended

Tarsier Pharma Ltd. is conducting an initial public offering (IPO) of its ordinary shares, targeting the treatment of immune-mediated eye diseases with high unmet need. The company's lead product, TRS01, is in Phase 3 development for non-infectious anterior uveitis, including uveitic glaucoma, with a pivotal trial (Tarsier-04) planned to evaluate IOP as the primary endpoint. The offering is contingent on NYSE American listing, and the company aims to commercialize TRS01 through a staged approach, focusing on uveitis specialists before expanding to broader markets. International expansion plans include partnerships in Europe, with ongoing dialogue with the EMA.

DRS/A amended

Tarsier Pharma Ltd. is conducting an initial public offering (IPO) of its ordinary shares, targeting non-infectious anterior uveitis, including patients with uveitic glaucoma. The company is advancing TRS01, a novel therapy, through a Phase 3 pivotal trial (Tarsier-04) with a primary endpoint focused on intraocular pressure (IOP) safety. The offering is underwritten by Konik Capital Partners, with plans to list on the NYSE American. The filing emphasizes the unmet medical need in uveitic glaucoma and outlines commercialization strategies, including targeted marketing to specialists and potential international expansion.

DRS filed

Tarsier Pharma Ltd. is conducting an initial public offering (IPO) for its ordinary shares, aiming to list on the NYSE American under the symbol 'TARX'. The company is developing TRS01, a novel therapy for non-infectious anterior uveitis, including patients with comorbid glaucoma. The offering is contingent on NYSE approval, and the company faces risks related to regulatory approvals, market competition, and reliance on key personnel. The IPO is underwritten by Konik Capital Partners, with proceeds intended to fund commercialization and further development of its pipeline.